Evaluate the combination of Irinotecan and Capecitabine in the first line treatment of advanced or metastatic gastric cancer

Introduction: Comes in gastric cancer nowadays second only to lung cancer as a cause of death following cancer, and ranked fourth in terms of falling, with 875,000 injured annually person in the world.Objectives of the study1 - the basic objectives• Determine objective response rate objective response rate (ORR) to participate, which includes both drug irinotecan, and capecitabine, as first-line treatment in advanced gastric cancer, or transitional.2 - Secondary objectives• measure the response time duration of response.• Measure the time that goes on before the disease begins our passage time to progression.• determine the extent of the safety of participating drug safety profile.• determine the overall survival overall survival.Patients & methods: The size of the sample assessed 45 patients, and has been started accepting patients in Dezful in July of 2014, and begin accepting patients at the Ganjavian Hospital in June of 2015, and ended up accepting patients in December of 2017, and from scheduled follow-up of patients follow-up up to 3-4 years.Monitoring follow-up: Text of the protocol to conduct clinical examination, and a full assessment, the patient responsive to treatment, and every three months after the end of treatment, while the remaining patients, is up to watch them, and assess their condition, when they visit the hospital, and in order to assess the survival College.Conclusion: Participation is therapeutic, which combines both of the following drugs irinotecan, and Capecitabine, treatment plans of the most promising in the treatment of advanced cancer of the stomach or in transition, where the response rate was recorded objective response is good, and acceptable side effects well-tolerated

Keywords:

Ganjavian Hospital , Capecitabine , irinotecan , Metastatic Gastric canc